Policy & Regulation
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
18 November 2026 -

Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) on Wednesday reported preliminary results from two Phase 3 studies evaluating investigational drug KarXT (xanomeline and trospium chloride) for psychosis associated with Alzheimer's disease, showing improvements in hallucinations, delusions and overall disease severity, with no new safety signals.

Data from the 12-week open-label lead-in of ADEPT-1 showed a mean 12-point reduction in hallucination and delusion scores from a baseline of 14.4 among 266 participants. Disease severity scores also improved, declining by a mean 1.9 points from 4.5. Of 320 participants enrolled, 85.3% completed the treatment period.

In the 52-week ADEPT-3 open-label extension, involving 401 participants, 68.1% completed treatment. Mean hallucination and delusion scores declined by 5.1 points from a baseline of 8.9, while disease severity scores improved by 0.8 points from 3.4. KarXT was generally well tolerated, with treatment-related adverse events leading to discontinuation in 4.7% of participants.

The findings, presented at the Clinical Trials on Alzheimer's Disease conference in Boston, represent the first clinical data disclosed from the ADEPT Phase 3 programme. Both studies remain ongoing, with results from their double-blind treatment periods still blinded.

KarXT, marketed as Cobenfy for schizophrenia in adults in the US, remains investigational for Alzheimer's-related psychosis. The wider ADEPT programme includes additional studies assessing acute efficacy and dosing.

Login
Username:

Password: